Searched for
FENOFIBRATE CAPSULES
Good news for diabetes & BP patients: Govt cuts prices of these 30 medicines, relief may reach pharmacies soon- Listen beyond the noise from Trump, think beyond Nifty’s volatility: 8 mid and 1 small cap pharma stock with upside potential of up to 46%
- Alembic Pharma gets USFDA nod for cholesterol lowering drug
- Top stocks in focus on Tuesday, 16 May 2017BPCL, HPCL and IOC will remain in focus on Tuesday16 May, 2017, 08.31 AM IST
- Alembic Pharma's cholesterol drug gets US FDA nodThe approved product is therapeutically equivalent to the reference listed drug product Trilipix Delayed-Release capsules of Abbvie Inc.15 May, 2017, 12.12 PM IST
- Ranbaxy Laboratories gets USFDA nod to sell cholesterol medicineRanbaxy received approval from USFDA to manufacture & market Fenofibrate capsules used for lowering high cholesterol & triglyceride levels ...05 Nov, 2014, 06.59 PM IST
- Dr. Reddy's Laboratories launches lipid controlling drug in USA marketThe drug which is indicated to reduce cholesterol and triglycerides (fatty acids) in the blood was approved by the United States Food & Dru...23 Apr, 2014, 04.39 PM IST
- Lupin launches generic Fenofibric Acid capsules in US marketLupin said its US arm has launched generic Fenofibric Acid capsules used for reducing cholesterol and fatty acids in the blood in the Ameri...06 Dec, 2013, 02.18 PM IST
- Lupin gets USFDA nod for additional strengths of cholesterol drug"Lupin Pharmaceuticals Inc (LPI), the company's US subsidiary would commence marketing the product shortly," Lupin said.22 Oct, 2013, 03.20 PM IST
- Lupin files second suit against RanbaxyMumbai-based drugmaker Lupin has filed a second suit in the US against Ranbaxy Laboratories to prevent the country’s largest drugmaker from...06 Apr, 2011, 05.02 AM IST
- Lupin drags Ranbaxy to US court over patent violationPharma major Lupin Ltd has filed a legal suit against rival Ranbaxy in the US, alleging patent violation of its cholesterol-lowering drug, ...09 Aug, 2010, 10.26 PM IST
- Citigroup maintains 'Buy' rating on LupinCitigroup maintains 'Buy' rating on Lupin and raises the target price to Rs 1,415, as they raise EPS estimates (FY10E/11E up 1%/14%) and ro...05 Oct, 2009, 08.00 AM IST
- Citi maintains 'buy' on LupinCiti has maintained its 'buy' rating on mid-sized Indian pharma firm Lupin, and raised its target price to Rs 1,415, following the acquisit...03 Oct, 2009, 03.30 AM IST
Load More
